Your browser doesn't support javascript.
loading
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
Strober, Bruce; Paul, Carle; Blauvelt, Andrew; Thaçi, Diamant; Puig, Luis; Lebwohl, Mark; White, Katy; Vanvoorden, Veerle; Deherder, Delphine; Gomez, Natalie Nunez; Eyerich, Kilian.
Afiliação
  • Strober B; Department of Dermatology, Yale University, New Haven, Connecticut; Central Connecticut Dermatology Research, Cromwell, Connecticut. Electronic address: brucestrober30@me.com.
  • Paul C; Toulouse University and INSERM Infinity, Toulouse, France.
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon.
  • Thaçi D; Insititute and Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
  • Puig L; Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, New York.
  • White K; UCB Pharma, Slough, United Kingdom.
  • Vanvoorden V; UCB Pharma, Brussels, Belgium.
  • Deherder D; UCB Pharma, Braine-l'Alleud, Belgium.
  • Gomez NN; Department of Dermatology, UCB Pharma, Monheim, Germany.
  • Eyerich K; Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany.
J Am Acad Dermatol ; 89(3): 486-495, 2023 09.
Article em En | MEDLINE | ID: mdl-37182701

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2023 Tipo de documento: Article